Strides Pharma Science: Appointment of Biren Gabhawala as Non- Executive Independent Director of the company w.e.f. November 01, 2026
Strides Pharma Science (STAR) filed a disclosure titled "Appointment of Biren Gabhawala as Non- Executive Independent Director of the company w.e.f. The company is valued at about ₹10,116 crore.
What happened
Strides Pharma Science (STAR) filed a disclosure with the exchanges on 29 October 2026 at 07:01 PM titled "Appointment of Biren Gabhawala as Non- Executive Independent Director of the company w.e.f. November 01, 2026".
From the filing: "Strides Pharma Science Limited has informed the Exchange regarding Appointment of Biren Gabhawala as Non- Executive Independent Director of the company w.e.f."
Company snapshot
Strides Pharma Science is a small-cap company in the Healthcare sector, with a market value of about ₹10,116 crore.
The stock last traded at ₹1,097.5, against a 52-week range of ₹768.7–₹1,260.9 (13.0% below the high).
Before this filing the shares had moved −8.4% over the month and +2.4% over three months. Average daily turnover over the last 20 sessions was about ₹29.53 crore.
Promoters held 27.91% at the end of Q1 FY27; 38.10% of promoter shares were pledged. Foreign institutions owned 28.39% and domestic institutions 15.41%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,120 | 99.6 | 10.81 |
| Q2 FY26 | 1,221 | 127.5 | 13.84 |
| Q3 FY26 | 1,195 | 202.1 | 21.93 |
| Q4 FY26 | 1,323 | 126.9 | 13.77 |
| Q1 FY27 | 1,265 | 156.9 | 17.02 |
What history shows
BCEIE has no earlier management change filing from this company on record since May 2026.
Across 109 similar disclosures by other Healthcare companies, shares moved +0.8% on average the next day and +1.7% over five days; 48% of them rose the next day.
Market-wide, 4,012 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- The appointment of a successor and any change in strategy or guidance.
- 29 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.